WuXi Biologics (Cayman) Performance dei guadagni passati

Il passato criteri di controllo 2/6

WuXi Biologics (Cayman) ha registrato una crescita degli utili a un tasso medio annuo di 23.7%, mentre il settore Life Sciences ha registrato utili in crescita a un tasso medio annuo di 20.1%. I ricavi sono stati in crescita a un tasso medio annuo di 32.7%. Il ritorno sul capitale proprio di WuXi Biologics (Cayman) è 6.7% e ha margini netti di 15.4%.

Informazioni chiave

23.7%

Tasso di crescita degli utili

22.3%

Tasso di crescita dell'EPS

Life Sciences Crescita del settore	41.4%
Tasso di crescita dei ricavi	32.7%
Rendimento del capitale proprio	6.7%
Margine netto	15.4%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come WuXi Biologics (Cayman) guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

SHSC:2269 Ricavi, spese e utili (CNY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	17,116	2,632	2,356	788
31 Mar 24	17,075	3,016	2,221	787
31 Dec 23	17,034	3,400	2,086	786
30 Sep 23	16,794	3,776	2,021	769
30 Jun 23	16,554	4,152	1,956	753
31 Mar 23	15,911	4,286	1,824	718
31 Dec 22	15,269	4,420	1,693	683
30 Sep 22	14,179	4,251	1,472	670
30 Jun 22	13,090	4,081	1,251	657
31 Mar 22	11,690	3,735	1,192	579
31 Dec 21	10,290	3,388	1,133	502
30 Sep 21	9,183	3,092	1,043	398
30 Jun 21	8,075	2,795	952	295
31 Mar 21	6,844	2,242	837	299
31 Dec 20	5,612	1,689	722	304
30 Sep 20	4,967	1,494	648	289
30 Jun 20	4,321	1,300	574	275
31 Mar 20	4,152	1,157	512	267
31 Dec 19	3,984	1,014	451	260
30 Sep 19	3,535	922	427	241
30 Jun 19	3,087	831	404	222
31 Mar 19	2,811	731	365	196
31 Dec 18	2,534	631	326	169
30 Sep 18	2,277	520	270	132
30 Jun 18	2,019	410	214	94
31 Mar 18	1,819	331	195	84
31 Dec 17	1,619	253	175	74
30 Sep 17	1,429	177	155	66
30 Jun 17	1,233	149	128	60
31 Mar 17	1,111	145	119	56
31 Dec 16	989	141	110	53
30 Sep 16	889	171	101	61
31 Dec 15	557	45	86	40
31 Dec 14	332	42	48	35

Guadagni di qualità: 2269 ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 2269 (15.4%) sono inferiori rispetto allo scorso anno (25.1%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 2269 sono cresciuti in modo significativo del 23.7% all'anno negli ultimi 5 anni.

Accelerare la crescita: 2269 ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: 2269 ha avuto una crescita negativa degli utili ( -36.6% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Life Sciences ( -2.3% ).

WuXi Biologics (Cayman) Performance dei guadagni passati

Il passato criteri di controllo 2/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week